These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31284859)
1. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis. Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859 [TBL] [Abstract][Full Text] [Related]
2. microRNAs as biomarkers of ovarian cancer. Zhang H; Lu B Expert Rev Anticancer Ther; 2020 May; 20(5):373-385. PubMed ID: 32326768 [No Abstract] [Full Text] [Related]
3. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer. Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568 [TBL] [Abstract][Full Text] [Related]
4. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003 [TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer. Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Gao YC; Wu J Tumour Biol; 2015 Jun; 36(6):4843-50. PubMed ID: 25636451 [TBL] [Abstract][Full Text] [Related]
7. Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview. Staicu CE; Predescu DV; Rusu CM; Radu BM; Cretoiu D; Suciu N; Crețoiu SM; Voinea SC Cells; 2020 Jan; 9(1):. PubMed ID: 31936634 [TBL] [Abstract][Full Text] [Related]
8. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. Guo F; Tian J; Lin Y; Jin Y; Wang L; Cui M J Int Med Res; 2013 Oct; 41(5):1456-61. PubMed ID: 23963852 [TBL] [Abstract][Full Text] [Related]
9. Role of a novel circulatory RNA-based biomarker panel expression in ovarian cancer. El-Shal AS; Matboli M; Abdelaziz AM; Morsy AA; Abdelbary EH IUBMB Life; 2019 Dec; 71(12):2031-2047. PubMed ID: 31520466 [TBL] [Abstract][Full Text] [Related]
10. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143 [TBL] [Abstract][Full Text] [Related]
11. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062 [TBL] [Abstract][Full Text] [Related]
14. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Xu YZ; Xi QH; Ge WL; Zhang XQ Asian Pac J Cancer Prev; 2013; 14(2):1057-60. PubMed ID: 23621186 [TBL] [Abstract][Full Text] [Related]
15. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644 [TBL] [Abstract][Full Text] [Related]
16. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048 [TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free microRNAs as clinical cancer biomarkers. Armand-Labit V; Pradines A Biomol Concepts; 2017 May; 8(2):61-81. PubMed ID: 28448269 [TBL] [Abstract][Full Text] [Related]
18. Wu L; Shang W; Zhao H; Rong G; Zhang Y; Xu T; Zhang J; Huang P; Wang F Dis Markers; 2019; 2019():7541857. PubMed ID: 31467618 [TBL] [Abstract][Full Text] [Related]
19. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009 [TBL] [Abstract][Full Text] [Related]
20. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. Márton É; Lukács J; Penyige A; Janka E; Hegedüs L; Soltész B; Méhes G; Póka R; Nagy B; Szilágyi M J Biotechnol; 2019 May; 297():58-65. PubMed ID: 30953675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]